<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193478</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-256-0102</org_study_id>
    <nct_id>NCT01193478</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Escalating, Multiple, Oral Doses of GS 5885 in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics
      and activity of escalating, multiple, oral doses of GS-5885 in subjects with chronic genotype
      1 Hepatitis C Virus (HCV) infection. Each participant in the study will be sequestered in the
      clinic for the initial 5 days of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects reporting an adverse event or experiencing a laboratory abnormality</measure>
    <time_frame>Safety and tolerability assessments will be performed up to Study Day 14 following administration of multiple doses of GS-5885 or placebo for 3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity measures: measured by change in plasma HCV RNA levels form baseline</measure>
    <time_frame>Assessed up to Study Day 14 following administration of multiple doses of GS-5885 or placebo for 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of GS-5885 plasma concentration over time</measure>
    <time_frame>Assessed up to Study Day 14 following administration of multiple doses of GS-5885 or placebo for 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of viral resistance</measure>
    <time_frame>Up to 48 weeks following Study Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GS-5885 (3 mg), once daily or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GS-5885 (10 mg), once daily or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GS-5885 (30 mg), once daily or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GS-5885 ( up to 90 mg), once daily or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GS-5885 (up to 90 mg), once daily or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 (optional)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GS-5885 (up to 90 mg), once daily or matching placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5885</intervention_name>
    <description>tablet, oral, 3 mg once daily for 3 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5885</intervention_name>
    <description>tablet, oral, 10 mg once daily for 3 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5885</intervention_name>
    <description>tablet, oral, 30 mg once daily for 3 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5885</intervention_name>
    <description>tablet, oral, up to 90 mg once daily for 3 days</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5885</intervention_name>
    <description>tablet, oral, up to 90 mg once daily for 3 days</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5885</intervention_name>
    <description>tablet, oral, up to 90 mg once daily for 3 days</description>
    <arm_group_label>Cohort 6 (optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 6 (optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronically infected with HCV genotype 1

          -  HCV treatment-naïve

          -  Not co-infected with HIV or HBV

          -  HCV RNA viral load of at least 100,000 IU/mL

          -  BMI 19 to 35 kg/m2

          -  Subject agrees to use highly effective contraception methods if female of childbearing
             potential or sexually active male.

        Exclusion Criteria:

          -  History of clinically-significant illness or any other major medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol

          -  Decompensated liver disease or cirrhosis or evidence of hepatocellular carcinoma

          -  Serological evidence of co-infection with human immunodeficiency virus (HIV),
             hepatitis B virus (HBV), or another HCV genotype

          -  Subjects with known, current use of amphetamines and/or cocaine; subjects taking
             methadone or buprenorphine (opioid replacement therapy) or ongoing alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Brainard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV RNA</keyword>
  <keyword>multiple ascending dose</keyword>
  <keyword>NS5A</keyword>
  <keyword>GS-5885</keyword>
  <keyword>chronic genotype 1 HCV infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

